Case presentation
We present a case of warfarin induced necrosis of the breast in a 38-year-old patient, treated with simple mastectomy.
On admission for breast necrosis, no fever was detected but the patient had a foul-smelling necrosis involving most of her left breast (Figure 1 ). Blood work showed INR, activated thromboplastin time (aPTT), and platelets of 1.32, 38 seconds, and 460,000 per cubic milliliter, respectively. Hematology consultation recommended discontinuation of warfarin and administration of Rivaroxaban.
Considering the extent of breast necrosis ( Figure  1) , mastectomy was recommended. Before surgery, Rivaroxaban was discontinued, and heparin and A 38-year-old female presented to the breast clinic of Imam Khomeini Hospital with the complaint of a necrotic ulcer on her left breast for 10 days. She had a history of admission for deep vein thrombosis (DVT) of the left lower limb one month earlier. The deep vein thrombosis occurred following long-term use of oral contraceptive pills (OCP). She received intravenous heparin followed by warfarin. She was discharged from the hospital with a daily dose of 10 mg of warfarin and with an INR of 2.1.
Warfarin is one of the most commonly prescribed oral anticoagulant medications, and it is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); and for thromboembolism prophylaxis in patients with valvular heart disease, mechanical heart valves, and atrial 1 fibrillation.
The most common complication of warfarin is 1 bleeding, which can be prevented by adjusting international normalized ratio (INR). Necrosis, osteoporosis, calcification, and purple toe syndrome are other side effects. Skin and subcutaneous tissue necrosis is an extremely rare and serious complication breast, but bilateral breast necrosis is also reported.
broad-spectrum antibiotics were started. The patient underwent left mastectomy. There were purulent secretions under the necrotic tissue and the wound was left open. Intravenous antibiotics were continued for 7 days. The wound irrigation and dressing were performed daily. The patient was discharged from the hospital with Rivaroxaban 7.5 mg/ twice a day for 21 days, then 20 mg/ day, and daily irrigation of the wound was arranged at a local clinic. Healing of the wound was monitored by the surgeon on a weekly basis. After one month, the wound was closed with abdominal advancement flap. Anticoagulation was continued for 6 months.
warfarin, and the majority of cases occur within 3 to 6 4, 6 days. However, there are reports of late-onset symptoms several years after commencement of [11] [12] [13] therapy. The initial manifestations of breast necrosis are paresthesia, pressure, and discomfort in the affected area. Later, erythematous or hemorrhagic skin lesions appear and will develop in to blisters and bullae, 4, 8 leading to skin necrosis and scar formation.
The exact pathogenesis of necrosis following warfarin usage is still unclear, however protein C deficiency, hypersensitivity, and direct toxic effect of 1, 6 warfarin are possible mechanisms of necrosis. The most popular pathogenesis is acute protein C deficiency. Warfarin blocks vitamin K epoxide reductase enzyme and inhibits synthesis of clotting factors II, VII, IX, and X. It also inhibits synthesis of The symptoms start 1 to10 days after initiation of It is important to consider other conditions that can mimic warfarin necrosis in differential diagnosis, such as micro-embolization (septic emboli, cholesterol emboli), heparin-induced skin necrosis as a result of the thrombocytopenia and thrombosis syndrome, disseminated intravascular coagulation, purpura fulminans, necrotizing fasciitis, cryoglobulinemia, inflammatory breast cancer, decubitus ulcers, snake venom induced skin necrosis, cellulitis, venous gangrene, necrotizing fasciitis, cellulitis, venous 1, 14 gangrene, calciphylaxis, and hematoma.
Management of breast necrosis following oral anticoagulation therapy with warfarin, starts with discontinuation of warfarin. However, withdrawing warfarin will not affect the course of the established 4, 5, 16 skin lesions.
Vitamin K and fresh-frozen plasma 8 are administered to replenish protein C levels, and anticoagulation should be continued by administering intravenous heparin or the non-vitamin K antagonist oral anticoagulants (NOACs) such as 17 Dabigatran or Rivaroxaban. The necrotic lesions should be managed surgically with debridement and
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In conclusion, fulminant painful purpura and erythematous skin lesions in patients receiving warfarin should be suspected as warfarin induced necrosis. Immediate discontinuation of warfarin, administration of vitamin K, and fresh-frozen plasma is recommended. The skin lesion should be managed with appropriate surgical debridement and wound care. hours to prevent clot formation.
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